Arca
Skip to content
Tools
Tools

Parkinson's disease

Drug research and approvals for parkinson's disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 513 studies of parkinson's disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 63 drug trials for it since 2013, FDA has 6 approved and 7 open orphan designations naming it, and the EU has 28 authorised medicines for it.

  • Recruiting worldwide: 513
  • Trials authorized in Canada: 63
  • FDA orphan approvals: 6
  • EU medicines: 28

Recruiting now

Newest posted first, of 513 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 24 of 29

Phase 3 12 of 35

Phase 2 12 of 113

Phase 1 or earlier 12 of 52

How its trials ended

3,950 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 648 whose ending is known, 42% met their primary endpoint, 6% missed it and 52% stopped early.

  • Completed, result not reported1,77645%
  • Ongoing92924%
  • Status unknown59715%
  • Met its primary endpoint2757%
  • Stopped: other or unclear1905%
  • Stopped: enrollment or feasibility722%
  • Missed its primary endpoint391%
  • Stopped: lack of efficacy261%
  • Stopped: sponsor or business decision251%
  • Stopped: funding18<1%
  • Stopped: safety3<1%

Trials authorized in Canada

The 10 newest of 63; search them all in Canada trials
Sep 2, 2026A phase 2 study to evaluate the efficacy, pharmacokinetics, safety, and tolerability of VIM0423 in adults with Parkinson’s disease tremor insufficiently…VIM0423 (VMA-1001 / VMA-1002)Vima Therapeutics, Inc.Pending
Aug 20, 2026Pharmacologically modulating the noradrenergic arousal system to reduce freezing of gait in Parkinson’s disease: a multi-center and multi-model approachAtomoxetineRadboud University Medical CenterPending
Jul 31, 2026A phase 1 safety and feasibility trial of focused ultrasound enhanced delivry of recombinant glucocerebrosidase in participants with Parkinson's diseaseDefinity (perflutren) / CerezymeSunnybrook Research InstitutePending
Jan 2, 2026Early longitudinal imaging in the Parkinson’s progression markers initiative using [18f] AV-133 (ppmi AV-133 prodromal imaging)[18F] AV-133The Michael J Fox Foundation for Parkinson's ResearchPending
Sep 23, 2025A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of intravenous prasinezumab in participants…Prasinezumab (RO7046015)RocheOngoing
Sep 11, 2025First-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of intrathecally administered…Aln-sncaRegeneronOngoing
Sep 11, 2025A phase 2/3, double-blind, placebo controlled study of BHV-8000 in participants with early Parkinson's diseaseBHV-8000Biohaven TherapeuticsPending
Sep 5, 2025Phase 3 study to assess the efficacy and safety of midbrain dopaminergic neuronal cell therapy (bemdaneprocel) for participants with Parkinson's diseaseBemdaneprocel / Basiliximab / Methylprednisolone acetate / Prednisone…Bluerock Therapeutics Canada ULCOngoing
Aug 15, 2025A phase 1/2 dose-escalation trial to evaluate safety, tolerability, and efficacy of a single dose of CAP-003 gene therapy administered to patients with…CAP-003 / Dexamethasone / PrednisoneCapsida Biotherapeutics, Inc.Pending
Dec 16, 2024Tallman family energizes research to help alleviate neuroinflammation in parkinsons disease-"taller than pd". a phase 2 futillity study to evaluate the…HydroxychloroquineOttawa Hospital Research InstituteOngoing

FDA orphan designations

Approved first, then open designations, newest first
Feb 3, 2025OnapgoTreatment of motor fluctuations in adults with advanced Parkinson’s diseaseMDD US Operations, LLCApproved
Oct 16, 2024VyalevTreatment of motor fluctuations in adults with advanced Parkinson's disease (PD)AbbVie, Inc.Approved
Aug 24, 2017GocovriTreatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy with or without concomitant dopminergic…Adamas Pharmaceuticals, Inc.Approved
Jan 9, 2015DuopaTreatment of motor flucuations in patients with advanced Parkinson's diseaseAbbVie, Inc.Approved
Apr 20, 2004ApokynFor the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose-wearing-off" and unpredictable :on/off" episodes)…MDD US Operations, LLCApproved
Jun 5, 1989EldeprylAs an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism,…Somerset Pharmaceuticals, Inc.Approved
Feb 8, 2016Eltoprazine HClTreatment of levodopa-induced dyskinesia associated with Parkinson's disease.Amarantus BioScience Holdings, Inc.Designated
Oct 20, 1997ApomorphineFor use as rescue treatment for early morning motor dysfunction in late-stage Parkinson's disease.Scherer DDSDesignated
Jul 18, 1997Allogeneic human retinal pigment epithelial cells on…Treatment of Hoehn and Yahr stage 3 and 4 Parkinson's disease.Bayer Healthcare Pharmaceuticals, Inc.Designated
Jun 24, 1997Porcine Sertoli cells aseptically prepared for…Treatment of Hoehn and Yahr stage four and five Parkinson's disease.Titan Pharmaceuticals, Inc.Designated
Dec 17, 1996Porcine fetal neural dopaminergic cells and/or precursors…Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.Diacrin/Genzyme LLCDesignated
Dec 17, 1996Porcine fetal neural dopaminergic cells and/or precursors…Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.Diacrin/Genzyme LLCDesignated
Jul 17, 1995ApomorphineTreatment of the on-off fluctuations associated with late-stage Parkinson's disease.Pentech Pharmaceuticals, Inc.Designated

Medicines authorised in the EU

Newest first; 15 of 28
Aug 20, 2026HopledoLevodopa; carbidopaZambon SpAEMA ↗
Apr 27, 2026OnerjiLevodopa; carbidopaTanabe Pharma GmbHEMA ↗
Sep 19, 2019InbrijaLevodopaMerz Therapeutics GmbHEMA ↗
Jun 24, 2016OngentysOpicaponeBial - Portela Cª, S.A.EMA ↗
Apr 4, 2016Rasagiline Viatris (previously Rasagiline Mylan)Rasagiline · genericViatris LimitedEMA ↗
Feb 23, 2015XadagoSafinamideZambon SpAEMA ↗
Jan 12, 2015Rasagiline ratiopharmRasagilineTeva B.V.EMA ↗
Nov 11, 2013Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz)Levodopa; carbidopa; entacaponeOrion CorporationEMA ↗
Aug 23, 2011Levodopa/Carbidopa/Entacapone OrionLevodopa; carbidopa; entacaponeOrion CorporationEMA ↗
Aug 18, 2011Entacapone OrionEntacaponeOrion CorporationEMA ↗
Jun 16, 2011Rivastigmine ActavisRivastigmine · genericActavis Group PTC ehfEMA ↗
Feb 18, 2011Entacapone TevaEntacapone · genericTeva Pharma B.V.EMA ↗
Dec 11, 2009Rivastigmine 1 A PharmaRivastigmine1 A Pharma GmbHEMA ↗
Dec 11, 2009Rivastigmine HexalRivastigmineHexal AGEMA ↗
Dec 10, 2009Rivastigmine SandozRivastigmineSandoz GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.